Literature DB >> 20001297

Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice.

Hongchi Jiang1, Weiyang Tao, Mu Zhang, Shangha Pan, Jagat R Kanwar, Xueying Sun.   

Abstract

This study investigated the use of low-dose metronomic (LDM) chemotherapy with paclitaxel in a highly metastatic mouse model of 4T1 breast cancers, and compared it with the maximum tolerable dose (MTD) therapy. LDM therapy displayed a stronger anti-tumor activity in suppressing primary and metastatic breast tumors with less degree of side effects, and stronger anti-angiogenic and anti-lymphangiogenic activities than MTD therapy. But MTD therapy showed stronger pro-apoptotic and anti-proliferative activities in situ. Paclitaxel therapy downregulated expression of vascular endothelial growth factor receptor-2 (VEGFR2) and up-regulated expression of thrombospondin-1. The results support the application of paclitaxel LDM therapy to treat advanced breast cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20001297     DOI： 10.3109/07357900902744510

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  11 in total

Review 1.  Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.

Authors:  Alexandra S Zimmer; Patricia S Steeg
Journal:  J Mol Med (Berl)       Date:  2014-11-22       Impact factor: 4.599

2.  Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.

Authors:  Mu Zhang; Chen Chen; Feng Su; Zhiguo Huang; Xiangmin Li; Xiaogang Li
Journal:  Technol Cancer Res Treat       Date:  2016-08-29

3.  Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.

Authors:  J J M A Hendrikx; J S Lagas; E Wagenaar; H Rosing; J H M Schellens; J H Beijnen; A H Schinkel
Journal:  Br J Cancer       Date:  2014-04-29       Impact factor: 7.640

4.  Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.

Authors:  Wei-Yang Tao; Xiao-Shuan Liang; Yang Liu; Chun-Yang Wang; Da Pang
Journal:  Int J Biol Sci       Date:  2015-01-01       Impact factor: 6.580

5.  Low-Dose Paclitaxel Inhibits Tumor Cell Growth by Regulating Glutaminolysis in Colorectal Carcinoma Cells.

Authors:  Chaoxiang Lv; Hao Qu; Wanyun Zhu; Kaixiang Xu; Anyong Xu; Baoyu Jia; Yubo Qing; Honghui Li; Hong-Jiang Wei; Hong-Ye Zhao
Journal:  Front Pharmacol       Date:  2017-05-04       Impact factor: 5.810

6.  Effect of rs67085638 in long non-coding RNA (CCAT1) on colon cancer chemoresistance to paclitaxel through modulating the microRNA-24-3p and FSCN1.

Authors:  Zhong-Sheng Xiao; Lei Zhao; Xiao-Ning Zhang; Han-Xian Li; Zhi-Hui Yin
Journal:  J Cell Mol Med       Date:  2021-03-11       Impact factor: 5.310

Review 7.  The pharmacological bases of the antiangiogenic activity of paclitaxel.

Authors:  Guido Bocci; Antonello Di Paolo; Romano Danesi
Journal:  Angiogenesis       Date:  2013-02-07       Impact factor: 9.596

8.  Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer.

Authors:  Toshiki Shimizu; Takashi Yokoi; Takeshi Tamaki; Kayoko Kibata; Noriko Inagaki; Shosaku Nomura
Journal:  Oncol Lett       Date:  2013-01-15       Impact factor: 2.967

9.  Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.

Authors:  Genevieve M Weir; Robert S Liwski; Marc Mansour
Journal:  Cancers (Basel)       Date:  2011-08-05       Impact factor: 6.639

10.  REDD1 is a determinant of low-dose metronomic doxorubicin-elicited endothelial cell dysfunction through downregulation of VEGFR-2/3 expression.

Authors:  Minsik Park; Joohwan Kim; Taesam Kim; Suji Kim; Wonjin Park; Kwon-Soo Ha; Sung Hwan Cho; Moo-Ho Won; Jeong-Hyung Lee; Young-Guen Kwon; Young-Myeong Kim
Journal:  Exp Mol Med       Date:  2021-10-25       Impact factor: 8.718
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.